Developing innovative drugs through the commons Lessons from the DNDi experience - Archive ouverte HAL Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2019

Developing innovative drugs through the commons Lessons from the DNDi experience

Résumé

In this paper we argue that DNDi, even though it belongs to the family of Product Development Partnerships (PDPs) created at the end of the 20th century, has followed a very particular trajectory, that allows us to characterize it as a distinctive commons in the field of public health. We illustrate this view by focusing on two features: DNDi’s promotion of collaborative platforms and its innovative intellectual property policy.
Fichier principal
Vignette du fichier
WP 33 DNDi as Commons.pdf (242.8 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03408089 , version 1 (28-10-2021)

Licence

Paternité - Partage selon les Conditions Initiales

Identifiants

  • HAL Id : hal-03408089 , version 1

Citer

Benjamin Coriat, P. Abécassis, J-F Alessandrini, Nathalie Coutinet, Stéphanie Leyronas. Developing innovative drugs through the commons Lessons from the DNDi experience. 2019. ⟨hal-03408089⟩
78 Consultations
36 Téléchargements

Partager

Gmail Facebook X LinkedIn More